University of Utah, Salt Lake City, Utah, UT, USA.
Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168.
Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes. In this article, we discuss the available second-line therapeutic options following docetaxel, with a special focus on cabazitaxel, which is the first agent to yield extended survival as second-line therapy following docetaxel. Cabazitaxel, a novel semi-synthetic taxane, is effective even in docetaxel-resistant model systems. Recently, results of the Phase III TROPIC trial demonstrated improved survival with cabazitaxel plus prednisone compared with mitoxantrone and prednisone in patients with progressive metastatic castration-resistant prostate cancer, following prior docetaxel, which led to approval by the US FDA.
多西他赛为基础的化疗治疗可改善转移性去势抵抗性前列腺癌患者的生存。然而，所有患者最终都会出现进展性疾病，导致预后不良。本文讨论了多西他赛治疗后的二线治疗选择，特别关注卡巴他赛，它是继多西他赛后作为二线治疗延长生存的首个药物。卡巴他赛是一种新型半合成紫杉烷，即使在多西他赛耐药的模型系统中也具有疗效。最近，III 期 TROPIC 试验的结果表明，与米托蒽醌和泼尼松相比，卡巴他赛加泼尼松可改善先前接受过多西他赛治疗的转移性去势抵抗性前列腺癌患者的生存，这导致美国 FDA 的批准。
